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Objective  To correlate existing evaluation tools with clinical information on Duchenne muscular dystrophy (DMD) 
patients following age and to investigate genetic mutation and its relationship with clinical function.
Method  Th   e medical records of 121 children with DMD who had visited the pediatric rehabilitation clinic from 
2006 to 2009 were reviewed. Th   e mean patient age was 9.9±3.4 years and all subjects were male. Collected data 
included Brooke scale, Vignos scale, bilateral shoulder abductor and knee extensor muscles power, passive range 
of motion (PROM) of ankle dorsi-flexion, angle of scoliosis, peak cough flow (PCF), fractional shortening (FS), 
genetic abnormalities, and use of steroid.
Results  The Brooke and Vignos scales were linearly increased with age (Brooke (y1), Vignos (y2), age (x), 
y1=0.345x-1.221, RBrooke
2=0.435, y2=0.813x-3.079, RVignos
2=0.558, p<0.001). In relation to the PROM of ankle dorsi-
fl  exion, there was a linear decrease in both ankles (right and left R
2=0.364, 0.372, p<0.001). Muscle power, Cobb 
angle, PCF, and FS showed diversity in their degrees, irrespective of age. Th   e genetic test for dystrophin identifi  ed 
exon deletions in 58.0% (69/119), duplications in 9.2% (11/119), and no deletions or duplications in 32.8% (39/119). 
Statistically, the genetic abnormalities and use of steroid were not defi  nitely associated with functional scale.
Conclusion  The Brooke scale, Vignos scale and PROM of ankle dorsi-flexion were partially available to assess 
DMD patients. However, this study demonstrates the limitations of preexisting scales and clinical parameters 
incomprehensively refl  ecting functional changes of DMD patients.
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INTRODUCTION
  Muscular dystrophy (MD) is a devastating inherited 
neuromuscular disease characterized by early onset 
and progressive course. Duchenne muscular dystrophy 
(DMD) is the most common subtype of MD with an inci-
dence of 1 in 3,500 to 6,000 live male births.
1 Th   e DMD is a 
pattern of X-linked recessive inheritance charac  terized by 
lack of dystrophin, which provides structural stability to 
the dystroglycan complex, located on the cell membrane 
within muscle tissues.
2,3 As a result, progressive proximal 
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muscle weakness usually appears in male children 
before age 5 years, and eventual gait diffi   culty follows. In 
general, DMD patients increasingly rely on a wheelchair 
by age 15 years, and death usually occurs before or at 20 
years of age.
4-6 As the disease progresses, most patients 
present various symptoms including joint contractures 
and muscle weakness in bilateral limbs, scoliosis, 
aggravated lumbar lordosis,
7 dilated cardiomyopathy,
8,9 
and dyspnea due to respiratory muscle failure.
10,11 Th  ere 
are different kinds of treatment options depending on 
the goal of treatment; steroids, such as Deflazacort for 
walking and cardiac function,
12,13 bracing for deformities 
of joints and spine, and physical or aqua therapies for 
weakness or poor general condition.
14 However, the 
aforementioned treatments only slow down the disease 
progression rather than provide a complete cure. At 
present, the life expectancy of DMD patients have been 
extended by the development of medical technology, 
an increase in rehabilitation facilities, and an increased 
accessibility of hospital for general medical care.
15 In 
addition, molecular and genetic therapies, such as exon 
skipping, mutation-specific treatment using nonsense 
codon suppressors, and gene therapy using viral and 
nonviral vectors, have been tried. Effects of these 
treatments are discussed, and expected to be used for the 
treatment of DMD patients in near future.
16-18
  There are a few objective functional scales for DMD 
patients, but these are not commonly used. Brooke scale 
is an evaluation tool for upper extremity function with 
limitations for estimating lower extremity function and 
joint contractures.
19 Vignos scale is a popular evaluation 
index primarily for lower extremity function, however, 
the grading is not clear.
19 In addition, according to an 
increased power wheelchair use led to reduced demand 
for orthosis, such as knee-ankle-foot orthosis (KAFO), 
subscales of the Vignos scale need to be revised. In 2006, 
Lue YJ et al. reported on the development of a muscular 
dystrophy-specific functional rating scale (MDFRS),
20 
which is a comprehensive evaluation tool that takes into 
account both upper and lower extremities function and 
contractures in MD. However, respiratory and cardiac 
functions are diffi   cult to check and have rarely been used 
in the clinical setting.
  Despite increased life expectancy and new developing 
treatment techniques, comprehensive and clinical 
evaluation tools are still lacking. Moreover whether 
the existing assessment tools accurately reflect the 
functioning of DMD patients has not reported in detail. 
In this study, the objective was to correlate clinical 
information to already existing assessment tools and age. 
Furthermore, we investigated the genetic mutation in the 
dystrophin gene and its relationship with function, as 
well as functional change following Defl  azacort use.
MATERIALS AND METHODS
Subjects
  Th   e medical records of DMD patients between January 
2006 and February 2009 at the pediatric rehabilitation 
clinic were reviewed retrospectively. All 121 subjects 
were male and had a mean age of 9.85±3.39 years at their 
fi  rst visit (Table 1). Th   e diagnosis of DMD was confi  rmed 
by genetic testing, muscle biopsy, and clinical findings 
by pediatrician and rehabilitation medicine specialist 
or previous diagnosis in another hospital. Evaluation 
exclusion criteria including Brooke scale, Vignos scale, 
and muscle power were; wearing splint or orthosis 
due to recent trauma or operation, medical problems 
(pneumonia that could affect the general condition), 
and a recently deteriorating condition due to seizures. 
Patients were also excluded from the study if records 
related to evaluation were incomplete because of poor 
cooperation.
Methods
  Items refl  ecting function and physical condition of DMD 
patients were selected from the medical records based 
Table 1. Characteristics of Patients
Variables Values
Age (years) 9.85±3.39 (n=121)
Sex All males (n=121)
Genetic abnormality (n=119)
  Deletion 69/119 (58.0%)
  Duplication 11/119 (9.2%)
  No deletion and duplication 39/119 (32.8%)
    No detected mutation 32/39
    Sequence variant 6/39
    Nonsense mutation 1/39
Using the Defl  azacort 93/121 (76.9%)
Values are mean±standard deviation or the total number.Il-Young Jung, et al.
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on previous studies. The selected items include Brooke 
scale, Vignos scale, passive range of motion (PROM, 
o) 
of bilateral ankle dorsi-flexion,
21-23 muscles power (N) 
of bilateral shoulder abductors (deltoid muscles) and 
knee extensors (quadriceps muscles),
21,24,25 Cobb angle 
(
o) to confi  rm scoliosis,
26-28 peak cough fl  ow (PCF, L/min) 
for respiratory function,
29,30 and fractional shortening 
(FS, %) for left ventricle function.
31 All items were not 
completely documented for each patient. Records of 
121 patients at initial visit, as well as follow up sessions 
(maximum of 6 sessions) were reviewed. Each item was 
measured by a physiatrist with the following standards. 
Brooke and Vignos scales were checked at every visits in 
outpatient clinic (Table 2). The PROM of bilateral ankle 
dorsi-fl  exion was measured in sitting or supine position 
with knees fl  exed to 90 degree by a goniometer with one 
axis parallel placed at the fi  bular shaft and the others at 
the fifth metatarsal bone. Passive dorsi-flexion range of 
the ankle was recorded as positive, neutral was recorded 
as 0, and plantar fl  exion contracture of ankle that limits 
dorsi-flexion was recorded as negative. Muscle power 
was assessed by hand held dynamometer FGN-50 (Nidec-
Shimpo corporation, Kyoto, Japan) at bilateral shoulder 
abductors and knee extensors referred to reported 
method by Palmieri et al.
25 Th   e shoulder abductor muscle 
power was examined from the lateral forearm when 
sitting upright, with the shoulder abducted to a 45 degree 
angle with the elbow was straight and with the forearm 
in a pronated position. Th   e knee extensor muscle power 
was examined from the anterior surface of distal shaft 
just proximal to ankle joint in the sitting position with a 
90 degree fl  exed position.
19 Cobb angle was the method 
of measuring kyphosis, and was defined as the angle 
between a line drawn parallel to superior endplate of 
the superior end vertebra and a second line drawn along 
the inferior end plate of the inferior end vertebra by 
Antero-Posterior view of whole spine on X-ray. Th  e  PCF 
was measured by flowmeter EN 13826 (Micro Medical, 
Basingstoke, UK) in a wheelchair or in the chair sitting 
position. Most patients’ PCF were tested more than twice, 
and values considered to be signifi  cant by the examiner 
were recorded. If PCF was tested only once, the result was 
recorded when checked value was judged as meaningful 
by the examiner. The FS, [(left ventricle end-diastolic 
diameter)–(left ventricle end-systolic diameter)×100]/
(left end-diastolic diameter), which refl  ect left ventricular 
function was measured by pediatric echocardiography.
32
  In addition to the above items, previous genetic test 
results were gathered according to type of genetic 
mutation, including exon deletion and duplication, no 
deletion and duplication, and the methods. There were 
119 available genetic results. Genetic test methods used 
were multiplex polymerase chain reaction (mPCR, 26 
sites: pb, pm, exons 3, 4, 6, 8, 12, 13, 16, 17, 19, 32, 34, 41, 
42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 60)
33 until July 2005, 
Table 2. Grading for Brooke and Vignos Scales
Grade Functional description
Brooke scale for upper extremity
1 Starting with arms at the sides, the patient can
 abduct the arms in a full circle until they touch
 above the head
2 Can raise arms above head only by fl  exing the
 elbow (shortening the circumference of the
 movement) or using accessory muscles
3 Cannot raise hands above head, but can raise
 an 8-oz glass of water to the mouth
4 Can raise hands to the mouth, but cannot raise
 an 8-oz glass of water to the mouth
5 Cannot raise hands to the mouth, but can use
 hands to hold a pen or pick up pennies from the
 table
6 Cannot raise hands to the mouth and has no
 useful function of hands
Vignos scale for lower extremity
1 Walks and climbs stairs without assistance
2 Walks and climbs stair with aid of railing
3 Walks and climbs stairs slowly with aid of railing
 (over 25 seconds for 8 standard steps)
4 Walks unassisted and rises from chair but cannot 
 climb stairs
5 Walks unassisted but cannot rise from chair or
 climb stairs
6 Walks only with assistance or walks
 independently with long leg braces
7 Walks in long leg braces but requires assistance
 for balance
8 Stands in long leg braces but unable to walk even
 with assistance
9 Is in a wheelchair
10 Is confi  ned to a bedThe Correlation of Function and Age with DMD
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and multiplex ligation-dependent probe amplification 
(MLPA)
34 since August 2005. Studies comparing exon 
deletion number with functional status have not been 
reported until now. Assuming an increased number 
of exons deletion, decrease functional status, and 
differences in the clinical items evaluated according to 
exon deletion number. Brooke scale, Vignos scale, and 
PROM of bilateral ankle dorsi-flexion were compared 
between single deletion and four or more exon deletion 
among the subjects with a highly frequent deletion site 
between exon 44 and 55. Ninety-three of the 121 patients 
were treated with Defl  azacort and 28 were not, and these 
data underwent analysis. The impact of Deflazacort, 
a type of steroid, which might have affected patient 
function, was confi  rmed using the Vignos scale to verify 
the risk of its eff  ect on the patients’ function in those who 
used it.
Statistics
  The correlation of each item with age was analyzed 
by linear regression model, and R square value (R
2) 
was confirmed by depicting trend line. Due to some 
missing data, a mixed model was applied to statistically 
analyze the data including functional status at specific 
age, clinical physical condition, and a serial functional 
change. In the genetic tests, difference of function 
depending on number of exon deletion (single versus 4 
and more exons deletions) was compared with Brooke 
scale, Vignos scale, and PROM of bilateral ankle dorsi-
fl  exion considering the age at the time of measurement. 
Mann-Whitney U-test, a nonparametric method, was 
used due to small number of subjects and without equal 
variance. Changes in Vignos scale according to used 
of Deflazacort were identified by regression analysis 
at Medical Research Collaborating Center (MRCC). 
The value of significance was set at p<0.05 and 95% 
confi  dence intervals (CI) were provided.
RESULTS
R square value of trend line per item
  Th   e higher the score, the more severe the decrement in 
function on the Brooke and Vignos scales. In the Brooke 
scale, total 252 scores in 90 of 121 patients were linearly 
increased according to increasing age, and R
2 of trend 
line was 0.435 (Brooke scale [y1], age [x], y1=0.345x-1.221, 
p<0.001) (Fig. 1-A). In Vignos scale, total 250 scores in 89 
of 121 patients were also linearly increased according to 
increasing age, and R
2 of trend line was 0.558 (Vignos scale 
[y2], age [x], y2=0.813x-3.079, p<0.001) (Fig. 1-B) which 
demonstrates lower extremity function was correlated 
relatively with age. Bilateral ankle dorsi-flexion angles 
showed a decreasing tendency as age increased. R square 
value for right was 0.364 (n=218, p<0.001, right ankle 
dorsi-fl  exion PROM (y1), age (x), y1=−4.535x+35.362) and 
R
2 for left was 0.372 (n=219, p<0.001, left ankle dorsi-
fl  exion PROM (y2), age (x), y2=−4.525x+35.568) (Fig. 2). In 
other words, as age increased, the more the ankle plantar 
contracture progressed in DMD.
  R square value was very low for bilateral shoulder 
Fig. 1. Th   e Brooke scale (A), and Vignos scale (B) of Duchenne muscular dystrophy patients with age. A score of 10 on the 
Vignos scale means dead (*p<0.001).Il-Young Jung, et al.
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Fig. 2. Correlation between age and right ankle dorsi-fl  exion PROM (A), and left ankle dorsi-fl  exion PROM (B), PROM: Passive 
range of motion (*p<0.001).
Fig. 3. Bilateral muscle power (N) with age, right (A) and left (B) shoulder abductor, right (C) and left (D) knee extensor.The Correlation of Function and Age with DMD
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abductor/knee extensor muscles power showing 0.026 
(n=59, p=0.219)/0.002 (n=87, p=0.659) on the right and 
0.007 (n=57, p=0.523)/0.001 (n=86, p=0.735) on the 
left (Fig. 3). There was no correlation between age and 
clinical indexes (Fig. 4), which included 43 cases of Cobb 
angle (n=40, R
2=0.001, p=0.828), 80 cases of PCF (n=59, 
R
2<0.001, p=0.926), and 84 cases of FS (n=56, R
2=0.003, 
p=0.624).
Genetic testing
  We reviewed 119 genetic results from 121 patients; 
records of genetic results were not present for 2 patients. 
The genetic mutation in 71 subjects (59.7%) was con-
firmed by MLPA, 22 (18.5%) by mPCR, and 16 (13.4%) 
by mPCR combined with MLPA. A specific method of 
genetic test was not recorded in 10 subjects; however, 
results of genetic mutation were recorded. Genetic 
abnormality was categorized by exon mutation, such as 
exon deletion of 67 (58%), duplication of 11 (9.2%), and 
no deletion or duplication of 39 (32.8%, Table 1). Among 
39 patients without deletion or duplication, sequence 
variant was verifi  ed at 6 and one patient had a nonsense 
mutation.
  In the 69 patients with deletions, the majority (30 pa-
tients) had a deletion of exon 50, other deletions 
included; 29 patients without exon 47, 28 patients without 
exon 46, and 28 patients without exon 49. It is well known 
that reported high frequently deletion sites are exon 1 
to 20 and 44 to 55; exon deletions in 8 patients (11.6%) 
were located within exon 1 to 20, 52 patients (75.4%) were 
located within exon 44 to 55, and 9 patients were situated 
at variable sites. Th   e number of single exon deletions was 
6 subjects at exon 45, 4 at exon 51, 2 at exons 44 and 50, 
and 1 at exons 12, 21 and 57. On classifying the patients 
according to the number of deficits between 44 and 55, 
the most common deletion site, a single exon deletion 
was found in 14 patients, 2 exons deletion in 7 patients, 
3 exons deletion in 10 patients, 4 exons deletion in 3 
Fig. 4. Relationship between age and Cobb angle for scoliosis 
(A), peak cough fl  ow (B), and fractional shortening (C).Il-Young Jung, et al.
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patients, and more than 5 exons deletion in 17 patients. 
The functional scales and gene deletions (single versus 
4 and more exons deletions) were compared, because 
the 4 exons deletion was the median value among the 
total number of deletion excluding single deletion 
base on number of patients. For patients with a single 
deletion, the mean Vignos scale score was 3.34±2.78 (12 
subjects/22 cases, mean age 11.81±3.95 years), the mean 
Brooke scale score was 1.22±0.52 (12 subjects/23 cases, 
mean age 12.21±4.28 years), and the right ankle dorsi-
flexion PROM was 5.94±12.60
o and left was 3.35±11.97° 
(9 subjects/17 cases, mean age 12.23±4.42 years). In 
patients with 4 and more deletions, the Vignos scale 
score was 4.80±3.47 and the Brooke score was 2.08±1.59 
(15 subjects/32 cases, mean age 10.00±2.33 years), the 
right ankle dorsi-flexion PROM was -6.89±23.15
o and 
the left was -8.64±22.85
o (13 subjects/28 cases, mean 
age 10.22±2.28 years, Table 3). On the Vignos scale, the 
diff  erence of age between the 2 groups was not signifi  cant 
(p=0.096) and difference in mean score, which was 
approximately scale 1, was not signifi  cant also (p=0.135). 
Th  e  diff  erence in Brooke scale was statistically signifi  cant 
between the 2 groups (p=0.032), however, upper 
extremity function in most patients was good (Brooke 
scale 1 or 2) for each group and the mean age of single 
exon deletion was higher than 4 or more deleted exons 
(p=0.04). Because of these biases, the clinical signifi  cance 
was unclear. Bilateral ankle dorsi-flexion PROM, mean 
scores of Brooke scale were not different between the 
2 groups on the left (p=0.064) and right (p=0.091), and 
mean age at time of exam (p=0.192).
Functional change ac cording to the use of Deﬂ  azacort
  Ninety-three (76.9%) patients of 121 used Deflazacort 
(Table 1). Th  e  eff  ects of using Defl  azacort were analyzed 
to change the Vignos scale, which was correlated with 
disease progression in the previous results. Contrary 
to previous research, patients with Deflazacort were at 
increased risk of an increasing Vignos scale compared 
with patients without Deflazacort. This result indirectly 
suggests that Vignos scale was not aff  ected by the use of 
Deflazacort or was increased by Deflazacort, however, 
this was not statistically signifi  cant (p=0.59).
DISCUSSION
  The strength of the study is that it had lots of data 
collected from many DMD patients and confined 
subjects to DMD patients instead of covering various 
kinds of MD, which made homogeneity enhanced. In 
addition, the study made a comprehensive evaluation 
of cardiopulmonary function by making good use of the 
Vignos scale, the Brooke scale, PCF, and FS. In addition, 
this study is significant in that it objectively examined 
the relationship between the change in patient function 
and age by the use of evaluation tools and lots of genetic 
information.
  The limitation of this study is that there is a great deal 
of missing data and it did not examine the change in 
patient functions by age, progressively. If there had been 
no missing data, we could have obtained a result by 
analyzing values measured according to change in age 
through Analysis of variance (ANOVA). However, this 
study could not examine the change in function, as there 
was missing data and age periods for evaluating function 
were different. In addition, the study used partial 
aspects of materials due to diffi   culty of grasping general 
condition of patients as the study was dependent upon 
retrospective study, which was dependent upon medical 
records. Besides, the study did not clearly distinguish 
Table 3. Relationship between the Number of Gene 
Deletion and Function
Single exon  
deletion 
(n=14)
Four and more 
exons deletion 
(n=20)
p-value
Vignos scale
  Age (years) 11.81±3.95 10.00±2.33 0.096 
  Degree  3.34±2.78  4.80±3.47 0.135 
Brooke scale
  Age (years) 12.21±4.28 10.00±2.33 0.040*
  Degree  1.22±0.52  2.08±1.59 0.036*
Right ADF PROM
  Age (years) 12.23±4.42 10.22±2.28 0.192 
  Degree (
o)  5.94±12.60 -6.89±23.15 0.064 
Left ADF PROM
  Age (years) 12.23±4.42 10.22±2.28 0.192 
  Degree (
o)  3.35±11.97 -8.64±22.85 0.091 
Values are mean±standard deviation.
ADF: Ankle dorsi-fl  exion, PROM: Passive range of motion
*p<0.05 by Mann-Whitney U-testThe Correlation of Function and Age with DMD
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BMD caused by in-frame deletion as genetic test of 
dystrophin gene conducted by our clinic did not check all 
sequences and the methods of gene diagnosis were not 
identical to each other.
  One of the purposes of this study was to examine 
whether evaluation tools showed a tendency properly 
that the functions weaken as the disease progresses 
and the age increases when functional evaluation tools 
are actually applied to DMD patients. To this end, the 
work on choosing items that can reflect the function 
and clinical status of DMD patients was conducted. 
Functional evaluation tools and clinical assessment 
of DMD patients reported by previous research were 
examined through expert meeting. A total 7 items, 
including cardiac assessment by adding signifi  cant items 
that were considered necessary and can be easily checked 
in outpatient clinics were determined. Gowers’ sign, in 
which a patient pushes himself up from his knee with his 
hand when he stands up after laying face down or sitting 
on the ground, was considered positive. In cases in which 
mental retardation (MR)
35 was confi  rmed and the case in 
which MR was not confi  rmed under Korean Educational 
Development Institute-Wechsler Intelligence Scale for 
Children (KEDI-WISC), and Korean-Child Behavior 
Checklist (K-CBCL) were distinguished by requesting the 
test child psychiatrist. Th   e relation between Gowers’ sign 
and deteriorating intelligence was not analyzed due to 
missing data and the diffi   culty in comparing according to 
change in age. Among the total 121 DMD patients, those 
who showed a positive Gowers’ sign were 24, those who 
showed negative reaction in Gowers’ sign were 9; and 
those who did not show clear reaction were 3 and those 
who did not have data were 85. There were 17 patients 
with MR; patients who did not show MR were 48 and 56 
patients did not have data.
  It was found that among tools that evaluate DMD 
patients, Vignos scale showed the pattern that increases 
linearly according to the change in age most signifi  cantly. 
Th  is  fi  nding means that the reduction in function appears 
linear in proportion to the increase in age and it is 
expected that Vignos scale will help predict the change in 
functions of DMD patients. It was found that the Brooke 
scale increased linearly in proportion to the increase 
in age, whereas PROM of bilateral ankle dorsi-flexion 
decreased. It is expected that these fi  ndings are useful in 
inferring the change in functions by age.
  It is reported that dilated cardiomyopathy is common 
in DMD patients, in particular those DMD patients who 
have diffi   culty in walking due to severe DMD.
10 However, 
this study found that FS did not decrease in proportion 
to an increase in age. This result may be attributed to 
the fact that most of the subjects in this study were in 
relatively good condition, which prevented the deterio-
ration in heart function from clearly being shown. 
As individual difference is large in FS, a significant 
result can be obtained when the change in patients is 
analyzed progressively; however, because the result of 
echocardiography used in this study was obtained by 
comparing the results at a certain point of subjects which 
prevented the deterioration of function being identifi  ed. 
It is estimated that the fact that this study did not evaluate 
the functioning of DMD patients by using the history 
of taking heart disease related medicines and B-type 
natriuretic peptide (BNP),
32 which is commonly used as 
an indicator of heart function and limited the evaluation 
of heart function. It was also found that bilateral 
shoulder abductor and knee extensor muscles power, 
Cobb angle and PCF did not show a linear increase or a 
linear decrease in proportion to age. It is estimated that 
the result may be attributed to the fact that muscular 
strength of DMD patients increased in the early stage, 
but decreases as DMD progresses and scoliosis develops 
in only some parts and worsens sharply in proportion to 
age.
  Dystrophin gene is located at Xp21.2 and large gene 
consisting of 79 exons with the size of 2.4 Mb. Deletion 
is most common in the dystrophin gene mutation and 
the generation of duplication was found in 5-10% of 
the patients
36 and variation, such as point mutations, 
microdeletions and microinsertions were found in 20-
30% of the patients.
37 Exon deletion, which is most 
common in dystrophin gene mutation, was found in 
58.0% (69/119) of the patients with similar findings in 
the results of previous research (55-65%). It was found 
that duplication was 9.2% (11/119), which coincides with 
result of previous studies.
36,38 The site of gene deletion 
generation is called a ‘hot spot’ and the hot spot is the 
fi  rst 20 exons located within 500 kb from the end of 5’ and 
is located between exon 44 and exon 55 located within 
1,200 kb from fi  rst exon.
39 It is reported that the deletion 
frequency is highest in the middle part of 1,200 kb.
33,36 
Th   is study revealed that greatest dystrophin gene deletion Il-Young Jung, et al.
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was found exon 50 that is located between exon 44 and 
55 and exon 46, exon 47, and exon 49 was highly frequent 
deletion site.
  Like DMD, BMD which is somewhat slight in symptoms 
can be generated by dystrophin gene deletion. If the 
deletion site moves the translational reading frame 
of mRNA, transcription ends in early stage in “out of 
frame deletion” and dystrophin protein is not formed 
and severe DMD is revealed. On the contrary, despite 
deletion, if the translational reading frame is preserved, 
abnormal protein or protein with small molecular mass 
generates in “in frame deletion” and slight BMD becomes 
revealed.
40 Two tests used by our hospital are known 
as the method that can accurately identify deletion 
and duplication in the dystrophin gene, but as mPCR 
selectively examines those exons in which deletion is 
common, mPCR is not enough to accurately identify gene 
deletion or duplication. Thus, our hospital reexamines 
patients by using MLPA though medical checkup and 
was done through mPCR in this case; whether there 
is deletion or duplication that is revealed through 
MLPA is examined. Statistical analysis was conducted 
through gene diagnosis after checking whether there 
was something remarkable in the results reported by 
the laboratory medicine department of our hospital.
33,41 
However, in MLPA implemented, the total genetic 
sequencing of dystrophin was not done and therefore it 
was impossible to gain information on in frame deletion 
and out of frame deletion.
  This study examined whether there is difference by 
comparing the Vignos and Brooke scales, PROM of 
bilateral ankle dorsi-flexion of patients who had single 
deletion and 4 or more deletions among deletions shown 
between exon 44 and 55. Comparisons were made under 
the assumption that the more exons deletion in DMD 
patients, the worse the function in DMD patients but 
statistical significance was not found except Brooke 
scale. In the case that score was recorded and the 
number of subjects was small, Brooke scale shows good 
function (1 or 2 point) and the diff  erence in age was not 
corrected, it was difficult to interpret that there was a 
difference in functioning. Further research is needed 
because functional scale showed a tendency of becoming 
deteriorated when there is 4 or more exon deletions. Th  e 
tools that can evaluate DMD patients comprehensively 
and objectively are needed for this type of further 
research and if such tools are developed and used, the 
correlation functions evaluated in the clinical setting and 
the result of gene diagnosis can be fully explained.
  The influence of steroids, which has been reported to 
delay natural progress of the disease, has on walking of 
DMD patients was examined,
11,12 and the result of this 
study was different from the report mentioned above. 
This difference may be attributed to the errors that 
Defl  azacort was used at the time when walking became 
not easy and drug therapy was given to the patients 
who showed deterioration of functions. This result is 
considered as limit that is shown in analysis which 
uses retrospective data and estimated as indication 
bias. Introducing a system that measures severity of the 
disease or introducing propensity scoring matching 
(PSM) that can evaluate the relation between various 
factors and medical treatments will help overcome 
indication bias.
  Th   e result of this study revealed that existing functional 
evaluation tools have limits in making a comprehensive 
evaluation of the functions of DMD patients. The tools 
such as Vignos scale and Brooke scale refl  ect the function 
of lower extremities and upper extremities separately 
and therefore they are not enough to check the change in 
comprehensive functions of DMD patients. Th  e  MDFRS 
has weakness that it requires lots of time and effort to 
apply it patients. Functional evaluation tools that can 
reflect the condition of DMD patients comprehensively 
and objectively and are easy to use have not been 
reported yet. This study showed the limit existing func-
tional evaluation tools have and the development of new 
functional evaluation tools that can check clinical eff  ect 
of medical treatment at this stage new remedies make 
appearances is needed.
CONCLUSION
  Th   e abilities of the Vignos scale for refl  ecting functional 
deterioration and the Brooke scale for decreasing 
ankle PROM as age increases in DMD patients were 
confi  rmed in this study. Also the results of exon deletion 
and duplication in 69 (58.0%) and 11 (9.2%) patients, 
respectively, resemble that of previous reports on DMD 
patients. Additionally, despite the statistical signifi  cance 
on the Brooke scale in those with single and 4 and more 
exons deletion at the ‘hot spot’ between exon 44 and 55, The Correlation of Function and Age with DMD
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supporting evidence for its clinical significance is still 
lacking. Differences in the Vignos scale and the PROM 
of bilateral ankle dorsi-flexion were not statistically 
signifi  cant.
  The study confirmed the limitation of currently used 
functional evaluation tools in reflecting functional 
deterioration according to age and only evaluating upper 
or lower extremity function in DMD patients. A recent 
increase in life expectancy of DMD patients and large 
clinical trials on new treatment methods require new 
functional evaluation tools for DMD patients that can 
reflect the clinical characteristics and quantitatively 
judge the treatment eff  ect, as well as accurately represent 
the functional deterioration as the disease progresses 
and integrated overall function of the DMD patients, to 
be developed.
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